RNA interference as a novel and powerful tool in immunopharmacological research

International Immunopharmacology

Volumn 7, Issue 4, 2007, Pages 417-426

  Kong, Yan ^a   Ruan, Lingfei ^a   Ma, Lili ^a   Cui, Youhong ^a   Wang, Ji Ming ^b   Le, Yingying ^a  

^a Chinese Academy of Sciences   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immune system; RNA interference; siRNA; Therapeutics

Indexed keywords

CD4 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHEMOTACTIC FACTOR; CYTOKINE; CYTOKINE RECEPTOR; DOUBLE STRANDED RNA; FIBRONECTIN; FORMYLPEPTIDE; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLIPOSOME; INTERLEUKIN 10; INTERLEUKIN 12; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; MICRORNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENETIC CONSERVATION; HUMAN; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG DESIGN; GENE TARGETING; HUMANS; IMMUNE SYSTEM DISEASES; RESEARCH; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 33847208906     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.12.011     Document Type: Review

References (92)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
2. Jorgensen R. Altered gene expression in plants due to trans interactions between homologous genes. Trends Biotechnol 8 (1990) 340-344
3. Guo S., and Kemphues K.J. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 81 (1995) 611-620
4. Romano N., and Macino G. Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol Microbiol 6 (1992) 3343-3353
5. Voinnet O. RNA silencing as a plant immune system against viruses. Trends Genet 17 (2001) 449-459
6. Denli A.M., and Hannon G.J. RNAi: an ever-growing puzzle. Trends Biochem Sci 28 (2003) 196-201
7. Mette M.F., Aufsatz W., van der Winden J., Matzke M.A., and Matzke A.J. Transcriptional silencing and promoter methylation triggered by double-stranded RNA. EMBO J 19 (2000) 5194-5201
8. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
9. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
10. Lee Y.S., Nakahara K., Pham J.W., Kim K., He Z., Sontheimer E.J., et al. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 117 (2004) 69-81
11. Hammond S.M., Bernstein E., Beach D., and Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404 (2000) 293-296
12. Elbashir S.M., Lendeckel W., and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15 (2001) 188-200
13. Nykanen A., Haley B., and Zamore P.D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107 (2001) 309-321
14. Khvorova A., Reynolds A., and Jayasena S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115 (2003) 209-216
15. Ahlquist P. RNA-dependent RNA polymerases, viruses, and RNA silencing. Science 296 (2002) 1270-1273
16. Billy E., Brondani V., Zhang H., Muller U., and Filipowicz W. Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci U S A 98 (2001) 14428-14433
17. Clemens M.J., and Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17 (1997) 503-524
18. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
19. Paul C.P., Good P.D., Winer I., and Engelke D.R. Effective expression of small interfering RNA in human cells. Nat Biotechnol 20 (2002) 505-508
20. Doench J.G., and Sharp P.A. Specificity of microRNA target selection in translational repression. Genes Dev 18 (2004) 504-511
21. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
22. Hutvagner G., and Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297 (2002) 2056-2060
23. Doench J.G., Petersen C.P., and Sharp P.A. siRNAs can function as miRNAs. Genes Dev 17 (2003) 438-442
24. Zeng Y., Yi R., and Cullen B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A 100 (2003) 9779-9784
25. Hutvagner G., and Zamore P.D. RNAi: nature abhors a double-strand. Curr Opin Genet Dev 12 (2002) 225-232
26. Lai E.C. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30 (2002) 363-364
27. Rhoades M.W., Reinhart B.J., Lim L.P., Burge C.B., Bartel B., and Bartel D.P. Prediction of plant microRNA targets. Cell 110 (2002) 513-520
28. Tuschl T., Zamore P.D., Lehmann R., Bartel D.P., and Sharp P.A. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 13 (1999) 3191-3197
29. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., and Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 22 (2004) 326-330
30. Chalk A.M., Wahlestedt C., and Sonnhammer E.L. Improved and automated prediction of effective siRNA. Biochem Biophys Res Commun 319 (2004) 264-274
31. Yuan B., Latek R., Hossbach M., Tuschl T., and Lewitter F. siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 32 (2004) W130-W134
32. Jagla B., Aulner N., Kelly P.D., Song D., Volchuk A., Zatorski A., et al. Sequence characteristics of functional siRNAs. RNA 11 (2005) 864-872
33. Shabalina S.A., Spiridonov A.N., and Ogurtsov A.Y. Computational models with thermodynamic and composition features improve siRNA design. BMC Bioinformatics 7 (2006) 65
34. Yiu S.M., Wong P.W., Lam T.W., Mui Y.C., Kung H.F., Lin M., et al. Filtering of ineffective siRNAs and improved siRNA design tool. Bioinformatics 21 (2005) 144-151
35. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-178
36. Amarzguioui M., Holen T., Babaie E., and Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31 (2003) 589-595
37. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G.J., et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31 (2003) 2705-2716
38. de Fougerolles A., Manoharan M., Meyers R., and Vornlocher H.P. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol 392 (2005) 278-296
39. Li C.X., Parker A., Menocal E., Xiang S., Borodyansky L., and Fruehauf J.H. Delivery of RNA interference. Cell Cycle 5 (2006) 2103-2109
40. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23 (2005) 1002-1007
41. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23 (2005) 709-717
42. Zhao H.F., L'Abbe D., Jolicoeur N., Wu M., Li Z., Yu Z., et al. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat Methods 2 (2005) 967-973
43. Xiang S., Fruehauf J., and Li C.J. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24 (2006) 697-702
44. Li H., Fu X., Chen Y., Hong Y., Tan Y., Cao H., et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 128 (2005) 2029-2041
45. Osada H., Tatematsu Y., Yatabe Y., Horio Y., and Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 65 (2005) 10680-10685
46. Ragozin S., Niemeier A., Laatsch A., Loeffler B., Merkel M., Beisiegel U., et al. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol 25 (2005) 1433-1438
47. Dittgen T., Nimmerjahn A., Komai S., Licznerski P., Waters J., Margrie T.W., et al. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proc Natl Acad Sci U S A 101 (2004) 18206-18211
48. Bahi A., Boyer F., Kolira M., and Dreyer J.L. In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J Neurochem 92 (2005) 1243-1255
49. Singer O., Marr R.A., Rockenstein E., Crews L., Coufal N.G., Gage F.H., et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8 (2005) 1343-1349
50. Nakamura H., Siddiqui S.S., Shen X., Malik A.B., Pulido J.S., Kumar N.M., et al. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 10 (2004) 703-711
51. Kushibiki T., Nagata-Nakajima N., Sugai M., Shimizu A., and Tabata Y. Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-beta type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds. J Control Release 110 (2006) 610-617
52. Le Y., Oppenheim J.J., and Wang J.M. Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev 12 (2001) 91-105
53. Le Y., Murphy P.M., and Wang J.M. Formyl-peptide receptors revisited. Trends Immunol 23 (2002) 541-548
54. Le Y., Iribarren P., Zhou Y., Gong W., Hu J., Zhang X., et al. Silencing the formylpeptide receptor FPR by short-interfering RNA. Mol Pharmacol 66 (2004) 1022-1028
55. Zhou Y., Bian X., Le Y., Gong W., Hu J., Zhang X., et al. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 97 (2005) 823-835
56. Chen Y., Stamatoyannopoulos G., and Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 63 (2003) 4801-4804
57. Smith M.C., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64 (2004) 8604-8612
58. Lapteva N., Yang A.G., Sanders D.E., Strube R.W., and Chen S.Y. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12 (2005) 84-89
59. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., and Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65 (2005) 967-971
60. Novina C.D., Murray M.F., Dykxhoorn D.M., Beresford P.J., Riess J., Lee S.K., et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 8 (2002) 681-686
61. Martinez M.A., Gutierrez A., Armand-Ugon M., Blanco J., Parera M., Gomez J., et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16 (2002) 2385-2390
62. Zhou N., Fang J., Mukhtar M., Acheampong E., and Pomerantz R.J. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 11 (2004) 1703-1712
63. Qin X.F., An D.S., Chen I.S., and Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 100 (2003) 183-188
64. Anderson J., and Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2 (2005) 1
65. Pinkenburg O., Platz J., Beisswenger C., Vogelmeier C., and Bals R. Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods 120 (2004) 119-122
66. Platz J., Pinkenburg O., Beisswenger C., Puchner A., Damm T., and Bals R. Application of small interfering RNA (siRNA) for modulation of airway epithelial gene expression. Oligonucleotides 15 (2005) 132-138
67. Roman-Blas J.A., and Jimenez S.A. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14 (2006) 839-848
68. Kubo M., Hanada T., and Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 4 (2003) 1169-1176
69. Shen L., Evel-Kabler K., Strube R., and Chen S.Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 22 (2004) 1546-1553
70. Song X.T., Evel-Kabler K., Rollins L., Aldrich M., Gao F., Huang X.F., et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 3 (2006) e11
71. Evel-Kabler K., and Chen S.Y. Inhibition of antigen-presentation attenuators to augment vaccines. Curr Opin Mol Ther 8 (2006) 24-30
72. Lee S.O., Lou W., Qureshi K.M., Mehraein-Ghomi F., Trump D.L., and Gao A.C. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60 (2004) 303-309
73. Gao L., Zhang L., Hu J., Li F., Shao Y., Zhao D., et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 11 (2005) 6333-6341
74. Gao L.F., Xu D.Q., Wen L.J., Zhang X.Y., Shao Y.T., and Zhao X.J. Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin 26 (2005) 377-383
75. Holtick U., Vockerodt M., Pinkert D., Schoof N., Sturzenhofecker B., Kussebi N., et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 19 (2005) 936-944
76. Hill J.A., Ichim T.E., Kusznieruk K.P., Li M., Huang X., Yan X., et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 17 (2003) 691-696
77. Flynn M.A., Casey D.G., Todryk S.M., and Mahon B.P. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm 1 (2004) 4 [Lond]
78. Liu G., Ng H., Akasaki Y., Yuan X., Ehtesham M., Yin D., et al. Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur J Immunol 34 (2004) 1680-1687
79. Sorensen D.R., Leirdal M., and Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327 (2003) 761-766
80. Schiffelers R.M., Xu J., Storm G., Woodle M.C., and Scaria P.V. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 52 (2005) 1314-1318
81. Khoury M., Louis-Plence P., Escriou V., Noel D., Largeau C., Cantos C., et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54 (2006) 1867-1877
82. Friese M.A., Wischhusen J., Wick W., Weiler M., Eisele G., Steinle A., et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64 (2004) 7596-7603
83. Takabatake Y., Isaka Y., Mizui M., Kawachi H., Shimizu F., Ito T., et al. Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 12 (2005) 965-973
84. Lomas-Neira J.L., Chung C.S., Wesche D.E., Perl M., and Ayala A. In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J Leukoc Biol 77 (2005) 846-853
85. Scacheri P.C., Rozenblatt-Rosen O., Caplen N.J., Wolfsberg T.G., Umayam L., Lee J.C., et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A 101 (2004) 1892-1897
86. Pebernard S., and Iggo R.D. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72 (2004) 103-111
87. Persengiev S.P., Zhu X., and Green M.R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10 (2004) 12-18
88. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., and Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5 (2003) 834-839
89. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11 (2005) 263-270
90. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348 (2005) 1079-1090
91. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 1197-1205
92. Thomas C.E., Ehrhardt A., and Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4 (2003) 346-358